Introduction and conclusions

European Urology

Volumn 39, Issue SUPPL. 3, 2001, Pages 1-5

  Chapple, Christopher R ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE; TAMSULOSIN;

BENIGN PROSTATE OBSTRUCTION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; COST OF ILLNESS; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; INCIDENCE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; URINARY TRACT DISEASE; MALE; REVIEW; URETHRA OBSTRUCTION;

CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HUMANS; MALE; PROSTATIC HYPERPLASIA; URETHRAL OBSTRUCTION;

EID: 0035070595     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052560     Document Type: Editorial

References (31)

1. High prevalence of benign prostatic hypertrophy in the community
2. LUTS suggestive of BPO. What are the current practice patterns?
3. LUTS suggestive of BPO. What is the available evidence for rational management?
4. Evidence based medicine: What it is and what it isn't
5. Evidence based medicine: An approach to clinical problem solving
6. Surgery
7. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia
8. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
9. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia
10. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia
11. Impact of prostate size on response to medical therapy for benign prostatic hyperplasia (BPH): Results of the PREDICT trial
12. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
13. Tamsulosin for the treatment of benign prostatic hypertrophy
14. Clinical practice guideline for benign prostatic hyperplasia: Diagnosis and treatment
15. Measuring the clinical appropriateness of the use of a procedure. Can we do it?
16. How can clinical expertise contribute to rational management?
17. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years
18. Natural history of prostatism: Longitudinal changes in voiding symptoms in community dwelling men
19. LUTS suggestive of BPO. What is the long-term effectiveness of medical therapies?
20. Natural history of prostatism: Risk factors for acute urinary retention
21. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists
22. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia
23. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
24. A 6-months large scale study into the safety of tamsulosin
25. LUTS suggestive of BPO. Triumph: Health-economical analysis
26. The ICS-BPH study: Uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction
27. LUTS suggestive of BPO. Triumph: The role of general practice databases